Pulmonx (NASDAQ:LUNG – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability.
Profitability
This table compares Pulmonx and KORU Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -60.09% | -92.94% | -39.80% |
| KORU Medical Systems | -5.27% | -13.61% | -8.33% |
Analyst Ratings
This is a breakdown of recent ratings for Pulmonx and KORU Medical Systems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 2 | 4 | 0 | 2.43 |
| KORU Medical Systems | 1 | 0 | 4 | 0 | 2.60 |
Risk and Volatility
Pulmonx has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.
Valuation and Earnings
This table compares Pulmonx and KORU Medical Systems”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulmonx | $90.50 million | 0.72 | -$54.00 million | ($1.30) | -1.19 |
| KORU Medical Systems | $41.13 million | 4.58 | -$2.64 million | ($0.05) | -82.00 |
KORU Medical Systems has lower revenue, but higher earnings than Pulmonx. KORU Medical Systems is trading at a lower price-to-earnings ratio than Pulmonx, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are owned by institutional investors. 6.8% of Pulmonx shares are owned by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
KORU Medical Systems beats Pulmonx on 9 of the 13 factors compared between the two stocks.
About Pulmonx
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
